Global Oncolytic Virus Landscape 2017: Key Players, Key Technologies, Projects, Business Deals and Private and Public Financing Rounds

Dublin, Jan. 31, 2017 -- Research and Markets has announced the addition of the "The Oncolytic Virus Landscape 2017: an Analysis of Pipeline, Stakeholders, Deals, Industry Trends & Opportunities" report to their offering.

This report "The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities" as of January 2017 brings you up-to-date regarding key players, key technologies, Oncolytic Virus projects, business deals and private and public financing rounds.

The report analyzes the Oncolytic Virus pipeline and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of oncolytic viruses in terms of partnering terms and conditions, venture and private financing and (initial) public offerings.

This report has been built in a bottom-up way by desktop search to identify and describe company, product, technology and business/financing profiles which then were evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities.

What will you find in the report?

• Selection of oncolytic virus strains
• Design & construction of engineered oncolytic viruses
• Herpes simplex virus (HSV) family
• Adenovirus-based oncolytic viruses
• Oncolytic Vaccinia Viruses, Vesicular Stomatitis Viruses, Newcastle Disease Viruses & Others
• Profiles of 45 oncolytic viruses in development and on the market;
• Analysis of the pipeline of oncolytic viruses
• Comparison of clinical development paths
• Combination trials of oncolytic viruses with immune checkpoint inhibitors
• Combination with other anticancer therapeutics
• Armed oncolytic viruses
• Tumor indication of oncolytic viruses under study
• Way of administration of oncolytic viruses in clinical studies
• Profiles of 45 companies active in the field of oncolytic viruses
• Pharma & Biotech vs four generations of oncolytic virus companies
• Stakeholder analysis within each peer group
• Sources of oncolytic virus technologies
• Sources of non-dilutive financing including partnering deals
• Analysis of venture and private equity financing rounds
• Listing on stock exchange for access to capital
• Mergers and acquisition in the field
• Trends in the further research and development of oncolytic viruses

Key Topics Covered:

1 Executive Summary

2 Introduction & Overview

3 Selection, Design & Construction of Oncolytic Viruses

4 Profiles of Oncolytic Viruses

5 Analysis of Oncolytic Virus Pipeline

6 Company Profiles

7 Stakeholder Analysis

8 Financing & Partnering

9 Trends & Opportunities

10 References

Companies Mentioned

• Amgen
• Astellas Pharma
• AstraZeneca (MedImmune)
• Bayer
• Benevir Biopharm
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Celgene
• Daiichi Sankyo
• Duke University start-up Company
• GSK (GlaxoSmithKline)
• GeneLux
• Green Cross
• Grifols
• IGNITE Immunotherapy
• Jiangsu Hengrui
• Merck
• Multivir
• Neotropix
• Oncolys BioPharma
• Oncolytics Biotech
• Oncorus
• Orca Therapeutics
• Oryx
• Otsuka Pharmaceutical Co
• Pfizer
• Roche
• Shanghai Sunway Biotech
• TILT Biotherapeutics
• VCN Biosciences
• ViraTherapeutics
• Viralytics
• Vyriad
• Wellstat Biologics
• Western Oncolytics

For more information about this report visit http://www.researchandmarkets.com/research/qfgfbc/the_oncolytic

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Infectious Diseases Drugs